Position in NVS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$5,575,375
New position
Shares Held
36,500
first reported quarter
Ownership
0.002%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026NATIXIS holds $664,875,786 across 10 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
707,790 | $179,757,426 | |
| 2 | LLY |
ELI LILLY & Co
|
133,441 | $160,053,151 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
2,519,137 | $145,152,673 | |
| 4 | ABBV |
AbbVie Inc.
|
267,055 | $67,201,720 | |
| 5 | NVO |
Novo Nordisk A S
|
824,229 | $39,513,538 | |
| 6 | MRK |
Merck & Co., Inc.
|
280,187 | $36,004,029 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
143,928 | $18,183,863 | |
| 8 | PFE |
Pfizer Inc
|
632,317 | $15,226,193 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,575,375 | 36,500 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||